Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNTA Stock Price Chart Interactive Chart >
CNTA Price/Volume Stats
|Current price||$3.85||52-week high||$9.95|
|Prev. close||$3.90||52-week low||$2.88|
|Day high||$3.99||Avg. volume||163,932|
|50-day MA||$3.69||Dividend yield||N/A|
|200-day MA||$4.02||Market Cap||364.19M|
Centessa Pharmaceuticals Limited (CNTA) Company Bio
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Most Popular Stories View All
CNTA Latest News Stream
|Loading, please wait...|
CNTA Latest Social Stream
View Full CNTA Social Stream
Latest CNTA News From Around the Web
Below are the latest news stories about CENTESSA PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023 – – Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist, as product candidate with the potential to be a best-in-class therapy to treat narcolepsy and o
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Genomic Medicines and Rare Disease DaysDate: Monday, April 3, 2023Location: New York, NYFireside Chat: 9:35 AM ET Event: Jefferies & Venrock Boston Bio
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?
Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines. “This is an exciting time for Centessa as we are focused on the next set of clinical milestones, including executing the pi
CNTA Price Returns
Loading social stream, please wait...